Specifically, the PCSK9 inhibitor, Pep2-8 trifluoroacetate at a dose of 10 μg/kg was administered at different time-points in an acute MI model: before ischaemia, during ischaemia and at the onset of reperfusion. This evidence concerns the gene PCSK9 and myocardial infarction.